Luke Lapointe's questions to Regenxbio Inc (RGNX) leadership • Q1 2025
Question
Speaking for Brian Skorney, Luke Lapointe of Baird asked if the company has set a target for the quantity of RGX-202 commercial product it expects to have available at launch.
Answer
President and CEO Curran Simpson explained that while a specific number is still under evaluation, the goal is to have a significant number of doses ready to quickly address the prevalent ambulatory market, which they estimate at 5,000-7,000 patients. He reiterated their facility can produce 2,500 doses annually, enabling them to build a substantial inventory before launch.